Physician profile
Alison E Collier
NPI 1639553753
$11,826.98
in general payments reported to CMS, 2019-2025
28 companies · $3,177 in 2025
The $3,177 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $2,073 · 2023: $2,864 · 2024: $2,775 · 2025: $3,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,578 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,578.13 |
| Education | $237.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,665.90 | 2021-2025 | |
| Janssen Biotech, INC. | $1,040.65 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $888.71 | 2021-2025 | |
| Ucb, INC. | $882.68 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $786.11 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $768.00 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $668.76 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $569.19 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Arcutis Biotherapeutics, INC. | $538.42 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $499.83 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $419.54 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $351.59 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $285.90 | 2021-2025 | |
| Incyte Corporation | $262.70 | 2022-2025 | Opzelura |
| Merz North America, INC. | $217.41 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $173.46 | 2024 | Otezla |
| Organon LLC | $166.37 | 2023-2025 | Vtama, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.42 | 2022-2023 | Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $113.46 | 2022-2025 | Cabtreo |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $58.15 | 2022-2023 | Valchlor |
| Organogenesis INC. | $56.65 | 2023-2025 | Puraply Wound Matrix, Puraply |
| Dermavant Sciences, INC. | $54.39 | 2023-2024 | Vtama |
| Allergan, INC. | $44.95 | 2022 | |
| Journey Medical Corporation | $42.07 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $24.97 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.60 | 2022 | |
| Botanix Sb INC | $18.15 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.